|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300077791 |
|
最近更新日期: Date of Last Refreshed on: |
2023-11-20 11:46:57 |
|
注册时间: Date of Registration: |
2023-11-20 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
针刺联合重复经颅磁刺激治疗卒中后抑郁的临床研究 |
|
Public title: |
Clinical study of acupuncture combined with repeated transcranial magnetic stimulation for the treatment of post-stroke depression |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
针刺联合重复经颅磁刺激治疗卒中后抑郁的临床研究 |
|
Scientific title: |
Clinical study of acupuncture combined with repeated transcranial magnetic stimulation for the treatment of post-stroke depression |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陈丽 |
研究负责人: |
何岳义 |
|
Applicant: |
Li Chen |
Study leader: |
Yueyi He |
|
申请注册联系人电话: Applicant telephone: |
+86 158 0280 3653 |
研究负责人电话:
Study leader's |
+86 136 1819 8153 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zuoyou0303@163.com |
研究负责人电子邮件: Study leader's E-mail: |
meishanheyueyi@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
四川省眉山市东坡区岷东大道北段9号 |
研究负责人通讯地址: |
四川省眉山市东坡区岷东大道北段9号 |
|
Applicant address: |
No. 9, North Section of Mindong Avenue, Dongpo District, Meishan City |
Study leader's address: |
No. 9, North Section of Mindong Avenue, Dongpo District, Meishan City |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
成都中医药大学附属眉山医院 |
||
|
Applicant's institution: |
Meishan Hospital of TCM Affiliated to ChengDu University of TCM |
||
|
研究负责人所在单位: |
成都中医药大学附属眉山医院 |
||
|
Affiliation of the Leader: |
Meishan Hospital of TCM Affiliated to ChengDu University of TCM |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2022-056 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
眉山市中医医院药物器械伦理委员会 |
||
|
Name of the ethic committee: |
Drug Device Ethics Committee of Meishan Hospital of Traditional Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-12-31 00:00:00 | ||
|
伦理委员会联系人: |
任静雯 |
||
|
Contact Name of the ethic committee: |
Jingwen Ren |
||
|
伦理委员会联系地址: |
四川省眉山市东坡区岷东大道北段9号 |
||
|
Contact Address of the ethic committee: |
No. 9, North Section of Mindong Avenue, Dongpo District, Meishan City |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 136 9905 8853 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
成都中医药大学附属眉山医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Meishan Hospital of TCM Affiliated to ChengDu University of TCM |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
四川省眉山市东坡区岷东大道北段9号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 9, North Section of Mindong Avenue, Dongpo District, Meishan City |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
四川省中医药管理局 |
||||||||||||||||||||||
|
Source(s) of funding: |
Sichuan Administration of Traditional Chinese Medicine |
||||||||||||||||||||||
|
研究疾病: |
脑卒中后抑郁 |
||||||||||||||||||||||
|
Target disease: |
Post-stroke depression |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
IV期临床试验 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
通过观察针刺联合重复经颅磁刺激(rTMS)治疗卒中后抑郁的临床疗效。证实针刺的有效性及安全性,为卒中后抑郁(PSD)患者寻找“简、验、效、廉”方案,提供新的思路和方法. |
||||||||||||||||||||||
|
Objectives of Study: |
The clinical efficacy of acupuncture combined with repetitive transcranial magnetic stimulation (rTMS) in the treatment of post-stroke depression was observed. It proves the effectiveness and safety of acupuncture, and provides new ideas and methods for patients with post-stroke depression (PSD) to find "simple, test, effective and cheap" solutions. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
①符合中医对中风及郁病的诊断标准,符合西医对脑卒中的诊断标准; ②卒中后1个月后并且病情稳定者,年龄35-75岁; ③汉密尔顿抑郁评定量表评分在21-35分、贝克抑郁自评量表评分在5-15分、蒙哥马利抑郁量表12-35分; ④发病前1个月未服用抗抑郁药物及其他影响精神类药物; ⑤无严重心、肝、肾等躯体疾病患者; ⑥自愿参加临床试验并签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Meet the diagnostic standards of stroke and depression in traditional Chinese medicine, and meet the diagnostic standards of stroke in Western medicine; (2) 1 month after stroke and stable condition, age 35-75 years old; (3) Hamilton Depression Rating Scale scores ranged from 21-35, Beck Depression Self-rating Scale scored 5-15 points, and Montgomery Depression Scale scored 12-35 points; (4) Not taking antidepressants and other psychotropic drugs 1 month before the onset of illness; (5) Patients without serious heart, liver, kidney and other physical diseases; (6) Voluntarily participate in clinical trials and sign informed consent. |
||||||||||||||||||||||
|
排除标准: |
①不符合上述诊断标准及纳入标准的患者 ②存在严重意识障碍、严重认知障碍或存在言语障碍不能配合的患者; ③合并其他精神障碍患者或体内有金属器件患者; ④伴有肝肾功不全,或心脑血管系统等重大疾病病情无法控制者; ⑤依从性可能较差或畏惧针灸者不能配合完成研究者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Patients who do not meet the diagnostic criteria and inclusion criteria of traditional Chinese and Western medicine (2) Patients with severe impairment of consciousness, severe cognitive impairment or speech impairment who cannot cooperate; (3) Patients with other mental disorders or patients with metal devices in the body; (4) Accompanied by liver and kidney dysfunction, or major diseases such as cardiovascular and cerebrovascular system cannot be controlled; (5) Those who may have poor compliance or fear of acupuncture cannot cooperate with the completion of the study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-04-01 00:00:00至 To 2025-03-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-11-30 00:00:00 至 To 2024-09-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
试验开始前采用SPSS生成随机数字序列,并装入不透明的信封中。受试者在签署了知情同意书后将获得内含随机数字的信封,在试验开始时研究人员根据信封内随机数字,按提前拟定好的随机方案对受试者进行分组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
A sequence of random numbers was generated using SPSS prior to the start of the experiment and packed into an opaque envelope. Subjects will receive envelopes containing random numbers after signing the informed consent form. At the beginning of the trial, the researchers grouped the subjects according to a randomized protocol drawn up in advance, based on the random numbers in the envelope. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
患者、评估者、数据管理者和统计者对试验分组均不知情。 |
|
Blinding: |
Patients, evaluators, data managers, and statisticians were not aware of the trial grouping. |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
研究是采用CRF表的形式采集数据 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The research collected data in the form of CRF tables |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |